One of the companies wanting to be part of the upcoming U.S. launch of Humira biosimilars is instead exploring options to raise additional capital so it can continue advancing its biosimilar pipeline ...
AbbVie Inc.’sABBV-0.18%decrease; red down pointing triangle arthritis therapy Humira is set to face its first competition in the U.S. from a near-identical copycat, the end of the exclusive run of ...
Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results